Surmodics (SRDX) Competitors

Integra LifeSciences (NASDAQ:IART) and Surmodics (NASDAQ:SRDX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations.

Is IART or SRDX more profitable?

Integra LifeSciences has a net margin of -0.42% compared to Surmodics' net margin of -11.48%. Integra LifeSciences' return on equity of 12.35% beat Surmodics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integra LifeSciences	-0.42%	12.35%	4.82%
Surmodics	-11.48%	-4.39%	-2.95%

Do analysts rate IART or SRDX?

Integra LifeSciences currently has a consensus target price of $18.63, suggesting a potential upside of 34.78%. Surmodics has a consensus target price of $43.00, suggesting a potential upside of 47.74%. Given Surmodics' stronger consensus rating and higher probable upside, analysts plainly believe Surmodics is more favorable than Integra LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integra LifeSciences	4 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.78
Surmodics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media refer more to IART or SRDX?

In the previous week, Integra LifeSciences had 6 more articles in the media than Surmodics. MarketBeat recorded 9 mentions for Integra LifeSciences and 3 mentions for Surmodics. Surmodics' average media sentiment score of 1.22 beat Integra LifeSciences' score of 0.67 indicating that Surmodics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integra LifeSciences	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Surmodics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings and valuation, IART or SRDX?

Integra LifeSciences has higher revenue and earnings than Surmodics. Integra LifeSciences is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integra LifeSciences	$1.62B	0.66	$67.74M	-$0.38	-36.37
Surmodics	$121.58M	3.42	-$11.54M	-$1.39	-20.94

Does the MarketBeat Community prefer IART or SRDX?

Integra LifeSciences received 101 more outperform votes than Surmodics when rated by MarketBeat users. However, 62.25% of users gave Surmodics an outperform vote while only 56.72% of users gave Integra LifeSciences an outperform vote.

Company	Underperform	Outperform
Integra LifeSciences	Outperform Votes 439 56.72%	Underperform Votes 335 43.28%
Surmodics	Outperform Votes 338 62.25%	Underperform Votes 205 37.75%

Which has more risk & volatility, IART or SRDX?

Integra LifeSciences has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Surmodics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in IART or SRDX?

84.8% of Integra LifeSciences shares are held by institutional investors. Comparatively, 96.6% of Surmodics shares are held by institutional investors. 3.5% of Integra LifeSciences shares are held by insiders. Comparatively, 8.9% of Surmodics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Integra LifeSciences and Surmodics tied by winning 9 of the 18 factors compared between the two stocks.